---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-130372"
form_type: "8-K"
ticker: "NMRA"
cik: "0001885522"
company_name: "Neumora Therapeutics, Inc."
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:27:14.745855+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Neumora FY2025 net loss $236.9M; NMRA-511 positive data; NMRA-215 delayed to Q1 2027; cash to Q3 2027

## Summary
- Cash $182.5M; FY net loss $236.9M; R&D $176.1M, G&A $60.1M; cash runway into Q3 2027.
- NMRA-511: pre-specified analysis (NPI-AA≥4) shows Cohen's d 0.34 on CMAI total, 0.51 on CMAI aggression.
- Navacaprant: KOASTAL-2 and -3 fully enrolled (>400 each); topline readout expected Q2 2026.
- M4 franchise: NMRA-898 lead; Phase 1 shows ~80-100h half-life, target engagement; MAD study data H2 2026.
- NMRA-215: 12-week DIO data supports switch/maintenance; tox finding in 5/142 rats; clinical now Q1 2027.

## SEC filing metadata
- accession: 0001193125-26-130372
- form_type: 8-K
- ticker: NMRA
- cik: 0001885522
- company_name: Neumora Therapeutics, Inc.
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1885522/000119312526130372/0001193125-26-130372-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1885522/000119312526130372/nmra-20260330.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-130372
- JSON: https://secwatch.observer/filing/0001193125-26-130372.json
- Plain text: https://secwatch.observer/filing/0001193125-26-130372.txt

## Key facts
- Earnings Releases
  Neumora Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.
  - Period: the fourth quarter and full year ended December 31, 2025
  - Result: reported results
  source text: On March 30, 2026, Neumora Therapeutics, Inc. (“Neumora” or the “Company”) announced its financial results for the fourth quarter and full year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1885522/000119312526130372/0001193125-26-130372-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.